Alphabet (GOOG/GOOGL) Reports 1Q'16 Results

Alphabet (GOOG/GOOGL) reported 1Q'02016 results when the market closed yesterday (02016.04.21).

I've be recording Google's (now Alphabet's) quarterly results since 4th-quarter 02008. Google reported 1Q'02016 results yesterday. In a nutshell: For the first 91 days of 02016, Alphabet generated $5.23 billion free cash flow while hiring 2,301 new workers and spending $2.428 billion on capital expenditures and paying an effective tax rate of 18%. Alphabet ended March with $75.264 billion in "cash." Seems like a decent quarter to me, yet right now (02016.04.22 at 7:42am MST) Alphabet has lost 5+% of its market price.

Illumina (ILMN) -- Heading For a New 52-Week Low?

Illumina (ILMN) lost 20+% of its market value when the market opened today (02016.04.19) after the company announced preliminary Q1'16 results that failed to match or exceed expectations. ILMN was at $139.09 at :40am EDT on 02016.04.19. 52-week range: $130.00 - $242.37. In other words, ILMN is approaching a new 52-week low. Hmm... Maybe we're nearing the end of the Genomics Age.

Red Hat (RHT) Gets an Upgrade by Some Investment Firm

Red Hat (RHT) was upgraded to "overweight" from "sector weight" at Pacific Crest (target price: $88). The GDT::Portfolio's target price is $101.22. RHT closed yesterday (02016.04.14) at $74.45. 52-week range: $59.59 - $84.44.

Finance.Yahoo.com: "Red Hat, Inc. provides open source software solutions to enterprise customers worldwide. It develops and offers operating system, virtualization, middleware, storage, and cloud technologies."

Adamis Pharmaceuticals (ADMP) Hits New 52-Week High

Adamis Pharmaceuticals (ADMP) spiked to a new 52-week high of $8.12 before closing yesterday (02016.04.14) at $8.07. Three months ago, on 02016.01.20, ADMP hit an intra-day low of $3.63. Yesterday's volume was 419,290 vs. 64,592. [There are ~13.46 million ADMP shares.] The GDT::Portfolio average cost per ADMP is $6.23, so at least our investment is currently above water.

Adamis is "focused on developing and commercializing products in the therapeutic areas of allergy and respiratory disease."

Keryx Biopharmaceuticals (KERX) Added to GDT::Portfolio

Keryx Biopharmaceuticals (KERX) was added to the GDT::Portfolio on 02016.04.01 (yes, April Fools' Day). We paid $4.55 per KERX share. " Keryx Biopharmaceuticals focuses on providing therapies for patients with renal disease in the United States."

Steven C. Gilman joined the Keryx board on 02016.03.31. Gilman is also on the board of Vericel (VCEL) and VCEL is a GDT::Portfolio stock.

Red Hat (RHT) Reports 4Q'16 Results

Red Hat (RHT) reported 4Q'16 results after the market closed yesterday (02016.03.22) and today (at 11:06am EDT) RHT is down almost 4% at $72.77. 52-week range: $59.59 - $84.44.

From the company's press release.

"Enterprises increasingly adopting hybrid cloud infrastructures and open source technologies drove our strong results. The fourth quarter marked our 56th consecutive quarter of revenue growth, contributing to Red Hat’s first fiscal year crossing $2 billion in total revenue," stated Jim Whitehurst, President and Chief Executive Officer of Red Hat.

On 02016.02.29, Red Hat $2.0 billion in cash and still had $237 million reserved to buyback RHT shares.

Vericel (VCEL) Pops on Huge Volume

Vericel (VCEL) closed today (02016.03.10) at $3.95, up 86.32%. Prior to the market opening the company issued a press having the headline: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy.

Previous close was $2.12. VCEL opened at $3.95 and hit an intra-day high of $4.90 (up 131%) before closing at $3.95. Volume was 29.8 million vs. 49,403.

About the volume... There are ~23.8 million VCEL shares and the float is ~15.3M. Today's volume was 29.8 million (i.e almost 2-times the float).